Want to hit Martin Shkreli in the face? Now’s your chance

Pharmaceutical chief Martin Shkreli listens on Capitol Hill in Washington, Thursday, Feb. 4, 2016, during the House Committee on Oversight and Reform Committee hearing on his former company's decision to raise the price of a lifesaving medicine. (AP Photo/Susan Walsh)

NEW YORK (WCMH/AP) — Martin Shkreli, the former hedge fund manager vilified for buying a pharmaceutical company and jacking up the price of a life-saving drug more than fiftyfold, says he’s auctioning off a chance to slap or punch him.

On his Twitter account, Shkreli says he’ll let someone slap or punch him in the face for a price to help the family of a friend who recently died.

To make an auction, a person needs to direct message Shkreli on Twitter.  As of Monday, Shkreli said the highest bid was $78,000.

Shkreli has found himself at the center of a firestorm over drug pricing in the last few months, and he hasn’t been afraid to throw on more fuel.

It began after his company, Turing Pharmaceuticals, spent $55 million in August for the U.S. rights to sell Daraprim, a 62-year-old drug for a rare parasitic infection, and promptly raised the price from $13.50 to $750 per pill.

The drug is the only approved treatment for toxoplasmosis, a disease that mainly strikes pregnant women, cancer patients and AIDS patients.

The move sparked outrage that resounded from the presidential campaign to the punk rock world and turned him into the new face of corporate greed.

Carrying an image of Turing Pharmaceuticals CEO Martin Shkreli in a makeshift cat litter pan, AIDS activists and others are asked to leave the lobby of 1177 6th Ave. in New York, Thursday, Oct. 1, 2015, during a protest highlighting pharmaceutical drug pricing. (AP Photo/Craig Ruttle)
Carrying an image of Turing Pharmaceuticals CEO Martin Shkreli in a makeshift cat litter pan, AIDS activists and others are asked to leave the lobby of 1177 6th Ave. in New York, Thursday, Oct. 1, 2015, during a protest highlighting pharmaceutical drug pricing. (AP Photo/Craig Ruttle)

Doctors and medical groups said the price hike was cutting off patients from lifesaving treatment, activists protested outside Turing’s offices, and the situation helped prompt a Senate hearing on drug prices.

Hillary Clinton called it price gouging and said the company’s behavior was “outrageous.” Donald Trump called Shkreli “a spoiled brat.” Bernie Sanders returned a donation from Shkreli. And indie record label Collect Records said it was severing ties with Shkreli, who had been an investor.

Pharmaceutical chief Martin Shkreli, right, and Nancy Retzlaff, Chief Commercial Officer of Turing Pharmaceuticals, are sworn in on Capitol Hill in Washington, Thursday, Feb. 4, 2016, prior to a House Committee on Oversight and Reform Committee hearing on his former company's decision to raise the price of a lifesaving medicine. (AP Photo/Susan Walsh)
Pharmaceutical chief Martin Shkreli, right, and Nancy Retzlaff, Chief Commercial Officer of Turing Pharmaceuticals, are sworn in on Capitol Hill in Washington, Thursday, Feb. 4, 2016, prior to a House Committee on Oversight and Reform Committee hearing on his former company’s decision to raise the price of a lifesaving medicine. (AP Photo/Susan Walsh)

Shkreli said the company would cut the price of Daraprim. However, Turing reneged. Instead, the company is reducing what it charges hospitals for Daraprim by as much as 50 percent.

While most patients’ copayments will be $10 or less a month, insurance companies will be stuck with the bulk of the tab, potentially driving up future treatment and insurance costs.

Shkreli has said that insurance and other programs allow patients to get the drug despite the cost, and that the profits are helping fund research into new treatments.

But he has also unapologetically emphasized a business-is-business argument for the price jump. In fact, he recently said he probably should have raised it more.


The original version of this story was first posted on WCMH’s website.